![Seth J. Orlow](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Seth J. Orlow
Director/Miembro de la Junta en ALMIRALL, S.A. .
Cargos activos de Seth J. Orlow
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ALMIRALL, S.A. | Director/Miembro de la Junta | 01/01/2016 | - |
Independent Dir/Board Member | 01/01/2016 | - | |
New York University | Corporate Officer/Principal | - | - |
R2 Dermatology, Inc. | Director/Miembro de la Junta | - | - |
R2 Technologies, Inc. (California)
![]() R2 Technologies, Inc. (California) Medical SpecialtiesHealth Technology R2 Technologies, Inc. is an American California-based company founded in 2014 by Irina Erenburg. The company specializes in developing groundbreaking technology that fights inflammation and provides precision cold treatment for the face and skin. The company's technology has been proven effective and is available for use in medical practices. The CEO is Tim Holt. | Director/Miembro de la Junta | - | - |
Nyu Grossman School of Medicine | Corporate Officer/Principal | 01/01/2006 | - |
Historial de carrera de Seth J. Orlow
Antiguos cargos conocidos de Seth J. Orlow.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Transave, Inc.
![]() Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Director/Miembro de la Junta | - | - |
Dermatology Foundation | Director/Miembro de la Junta | - | - |
Anaderm Research Corp. | Fundador | - | - |
Ivrea Pharmaceuticals, Inc.
![]() Ivrea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ivrea Pharmaceuticals, Inc. develops pharmaceuticals for dermatologic conditions. The company's clinical trials include IVR 101/102 and IVR 103. Ivrea Pharmaceuticals was founded by Maurizio V. Cattaneo in May 2005 and is headquartered in Quincy, MA. | Director/Miembro de la Junta | 01/01/2005 | - |
Fundador | 01/01/2005 | - | |
░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | ░░░░░░░░░░ |
Formación de Seth J. Orlow.
Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Harvard College | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 14 |
España | 2 |
Operativa
Director/Board Member | 8 |
Corporate Officer/Principal | 3 |
Founder | 2 |
Sectorial
Health Technology | 7 |
Consumer Services | 5 |
Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ALMIRALL, S.A. | Health Technology |
Empresas privadas | 9 |
---|---|
Easton Capital Investment Group
![]() Easton Capital Investment Group Investment ManagersFinance Easton Capital Investment Group (Easton) is a Venture Capital firm which is founded in 2000 by John H. Friedman. The firm is headquartered in New York ,US. | Finance |
Protez Pharmaceuticals, Inc.
![]() Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Health Technology |
Coapt Systems, Inc.
![]() Coapt Systems, Inc. BiotechnologyHealth Technology Coapt Systems, Inc. designs, develops, manufactures and markets bio absorbable implants for surgeons to use in plastic surgery to fixate soft tissue to other soft tissue and bone. The company was founded in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Ivrea Pharmaceuticals, Inc.
![]() Ivrea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ivrea Pharmaceuticals, Inc. develops pharmaceuticals for dermatologic conditions. The company's clinical trials include IVR 101/102 and IVR 103. Ivrea Pharmaceuticals was founded by Maurizio V. Cattaneo in May 2005 and is headquartered in Quincy, MA. | Health Technology |
Anaderm Research Corp. | |
R2 Dermatology, Inc. | |
Transave, Inc.
![]() Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
Dermatology Foundation | |
R2 Technologies, Inc. (California)
![]() R2 Technologies, Inc. (California) Medical SpecialtiesHealth Technology R2 Technologies, Inc. is an American California-based company founded in 2014 by Irina Erenburg. The company specializes in developing groundbreaking technology that fights inflammation and provides precision cold treatment for the face and skin. The company's technology has been proven effective and is available for use in medical practices. The CEO is Tim Holt. | Health Technology |
- Bolsa de valores
- Insiders
- Seth J. Orlow
- Experiencia